Biological Autoimmune Therapeutics


biological autoimmune therapeutics          Published November 2018 •  Catalog no. RJT977K  •  Price US $3,850



 

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration.  Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward user acceptance and designed-in usability. The influence of biosimilars on as-supplied packaging strategies is yet to be determined, but the need for product differentiation in an increasingly crowded market segment will make product packaging a key competitive factor.

Bar_Graph Biological Autoimmune Therapeutics Report Brochure (Download PDF)

Blue document  Biological Autoimmune Therapeutics Report Order Form (Download PDF)

 

  Click HERE to Order Online

 


Biological Autoimmune Therapeutics – What You Will Learn

•   What are the approved biological drugs indicated for autoimmune conditions, what is the as-supplied packaging, and who markets them?
•   What are the major factors driving the growth of biological drugs for treating autoimmunity?
•  What is the size of the market biological autoimmune therapeutics drugs today, who are the market share leaders, and what will it be in 2022?
•  How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
•  What are the essential design factors, technologies and market development issues for biological autoimmune drugs?
•  What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?


Biological Autoimmune Therapeutics – Summary of Contents

Executive Summary

Market Dynamics

Unmet Patient Needs
Drug Development
Patient Population Factors

The Autoimmune Patient

The Informed Patient
Product Design & Patient Enablement Factors
Ease of Use
Patient Adherence
Dosing Frequency

Product Landscape

Biosimilars
Regional Market Product Strategies

As-Supplied Packaging and Administration

Device Selection – Stability and Material Issues
Human Engineering/Ergonomics
Pre- and Post-Marketing Device Evolution
The Role of Prefilled Devices
Prefilled Syringes
Autoinjectors
Special Feature Autoinjectors
Pen Injectors
Emerging Devices

The Product Ecosystem

Supplier Relationships
Supplier Resources – Geographic Distribution
Drug Supply Chain Activity

Product Analysis, Financial Performance & Forecasts

Development-stage Therapeutics

Autoimmune Therapeutics – Market Segment Analysis

Ankylosing Spondylitis
Crohn’s Disease
Adult Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Multiple Sclerosis
Psoriatic Arthritis
Ulcerative Colitis

Market Factors

Regulatory Factors
United State/FDA
Europe/EMA
Clinical Trial Protocols & Endpoints
Alliances and Partnerships

Company Profiles


 

View Press Release